Engineering topics

Song, Jeongseog

Publications and source records attributed to Song, Jeongseog.

7 records

DOE OSTI2024

FRIB Beam Power Ramp-up: Status and Plans

After project completion on scope, on cost, and ahead of schedule, the Facility for Rare Isotope Beams began operations for scientific users in May of 2022. The ramp-up to a beam power of 400 kW is planned over a six-year period; 1 kW was delivered for initial user runs from in 2022, and 5 kW was delivered as of February 2023. Test runs with 10 kW 36Ar and 48Ca beams were conducted in July 2023. Upgrade plans include doubling the primary-beam energy to 400 MeV/nucleon for enhanced discovery potential (¿FRIB 400¿). This talk reports on the strategic plans towards high power operations emphasizing challenges and resolutions in beam-interception devices and targetry systems, radiation protection and controls, and legacy system renovation and integration.

43 PARTICLE ACCELERATORS↗

DOE OSTI2023

FRIB Transition to User Operations, Power Ramp Up, and Upgrade Perspectives

After project completion on scope, on cost, and ahead of schedule, the Facility for Rare Isotope Beams began operations for scientific users in May of 2022. During the first 12 months of user operations, the FRIB accelerator complex delivered 5250 beam hours, including 1528 hours to nine science experiments conducted with primary beams of 36Ar, 48Ca, 70Zn, 82Se, 124Xe, and 198Pt at beam energies >200 MeV/u; 2724 hours for beam developments, studies, and tuning; and 998 hours to industrial users and non-scientific programs using the FRIB Single Event Effect (FSEE) beam line. The ramp-up to a beam power of 400 kW is planned over a six-year period; 1 kW was delivered for initial user runs from in 2022, and 5 kW was delivered as of February 2023. Upgrade plans include doubling the primary-beam energy to 400 MeV/nucleon for enhanced discovery potential (¿FRIB 400¿). This talk reports on FRIB status and progress since SRF2021, emphasizing lessons learned during the transition from beam commissioning to machine operations, challenges and resolutions for the power ramp-up, progress with accelerator improvements, and R&D for the energy upgrade.

43 PARTICLE ACCELERATORS↗

DOE OSTI2023

Photonuclear production of 47 Ca for 47 Ca/ 47 Sc generator from natural CaCO 3 targets

Here this work investigated the indirect production of 47 Sc from natural Ca targets via 48 Ca(γ,n) 47 Ca → 47 Sc +β - +$\bar{\nu}_e$ with incident electron energies of 30, 35, and 40 MeV. The 47 Ca production yields were simulated using the PHITS Monte Carlo simulation code and compared to experimental data. The simulated production rates for all three irradiations are in good agreement with experimental data within uncertainties. As a demonstration of the 47 Ca/ 47 Sc generator system, one of the irradiated CaCO 3 targets was dissolved in nitric acid, and 47 Sc was isolated from the target material using commercially available Eichrom DGA resin. The 47 Sc was allowed to grow in, and the purification process was repeated with promising 47 Sc and Ca recovery yields.

07 ISOTOPE AND RADIATION SOURCES↗

DOE OSTI2022

Compact assembly for production of medical isotopes via photonuclear reactions

The invention provides a method for generating medical isotopes, the method comprising contacting a primary radiation beam with a converter for a time sufficient to produce a secondary beam of gamma particles, and contacting the beam of gamma particles to a target, where the cross section dimension of the beam of gamma particles is similar to the cross section dimension of the target. Both the converter and target are small in diameter and very closely spaced. Also provided is a system for producing medical isotopes, the device comprising a housing having a first upstream end and a second downstream end, a radiotransparent channel (collimator) with a first upstream end and a downstream end, wherein the upstream end is adapted to receive a radiation beam, a target positioned downstream of the downstream end of the channel and coaxially aligned with the channel, wherein the target has a cross section that is similar to the cross section of the channel.

Nolen, Jr., Jerry A.↗

DOE OSTI2021

Half-life of 67 Cu

The half-life of 67 Cu was determined through serial gamma-ray spectrometry measurements of the dominant gamma emission (E γ : 184.6 keV; branching ratio: 48.7%) produced following β- decay. Data were collected consecutively for 1000 s per measurement, with a total of 3063 measurements over the duration of 36 days. The incidence rate for the 184.6 keV gamma-ray was determined from the spectral peak area and duration of each measurement. This rate was then corrected to account for detector dead-time, radioactive decay during each acquisition and drift in the computer clock in comparison to NIST nuclear clock. Least-squares regression analysis was performed to determine the half-life of 67 Cu. The result was 61.761 ± 0.004 h, which is the highest precision measurement to date, and marks a 24-fold precision improvement over the current Nuclear Data Sheets value.

73 NUCLEAR PHYSICS AND RADIATION PHYSICS↗

DOE OSTI2021

Imaging and dosimetric characteristics of 67 Cu

In recent years the use of beta-emitting radiopharmaceuticals for cancer therapy has expanded rapidly following development of therapeutics for neuroendocrine tumors, prostate cancer, and other oncologic malignancies. One emerging beta-emitting radioisotope of interest for therapy is 67 Cu (t 1/2 : 2.6 d) due to its chemical equivalency with the widely-established positron-emitting isotope 64 Cu (t 1/2 : 12.7 h). Here we evaluate both the imaging and dosimetric characteristics of 67 Cu, as well as producing the first report of SPECT/CT imaging using 67 Cu. To this end, 67 Cu was produced by photon-induced reactions on isotopically-enriched 68 Zn at the Low-Energy Accelerator Facility (LEAF) of Argonne National Laboratory, followed by bulk separation of metallic 68 Zn by sublimation and radiochemical purification by column chromatography. Gamma spectrometry was performed by efficiency-calibrated high-purity germanium (HPGe) analysis to verify absolute activity calibration and establish radionuclidic purity. Absolute activity measurements corroborated manufacturer-recommended dose-calibrator settings and no radionuclidic impurities were observed. Using the Clinical Trials Network anthropomorphic chest phantom, SPECT/CT images were acquired. Medium Energy (ME) SPECT collimation was found to provide the best image quality from the primary 185 keV gamma emission of 67 Cu. Reconstructed images of 67 Cu were similar in quality to images acquired using 177 Lu. Recovery coefficients were calculated and compared against quantitative images of 99m Tc, 177 Lu, and 64 Cu within the same anthropomorphic chest phantom. Production and clinical imaging of 67 Cu appears feasible, and future studies investigating the therapeutic efficacy of 67 Cu-based radiopharmaceuticals are warranted.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

DOE OSTI2020

Side-reaction products identified for photo-nuclear production of 99 Mo

Production of 99 Mo by the 100 Mo (γ, n) 99 Mo reaction through the bremsstrahlung process using an electron accelerator is one of the feasible options currently pursued by several countries. In this work, we report experimental results on identification of side-reaction products after the irradiation of natural and enriched 100 Mo targets. Side-reaction products identified include various Mo, Nb and Zr isotopes. Comparison of experimentally determined reaction production rates with those determined based on theoretical cross-sections will be presented. Moreover, activation products formed due to presence of impurities introduced during the manufacturing of the Mo targets will also be discussed.

38 RADIATION CHEMISTRY, RADIOCHEMISTRY, AND NUCLEA↗